Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II proof-of-concept study of itepekimab in uncontrolled chronic rhinosinusitis without nasal polyps
CTR20250178Phase 2Completed
- Sponsor
- Sanofi
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of itepekimab in chronic rhinosinusitis (CRS), sponsored by Sanofi. Started Apr 2025; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on CTR20250178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250178.